托珠单抗治疗激素抵抗或不耐受的中重度甲状腺相关性眼病临床疗效的Meta分析

doi:10.6040/j.issn.1673-3770.0.2024.389

摘要/Abstract

摘要： 目的探究托珠单抗(tocilizumab, TCZ)治疗激素抵抗或不耐受的中重度甲状腺相关性眼病(thyroid associated ophthalmopathy, TAO)的临床疗效。方法通过检索中英文数据库(中国知网、中国生物医学、万方、维普、PubMed、Web-of-science、Embase和Cochrane),检索范围从建库~2024年4月11日发表的关于托珠单抗治疗激素抵抗或不耐受的中重度甲状腺相关眼病的临床研究。评价指标包括临床活动性评分(clinical activity score, CAS)、突眼度、甲状腺刺激免疫球蛋白(thyroid stimulating immunoglobulin, TSI)或促甲状腺激素受体抗体(thyrotropin receptor antibody, TRAb)和不良反应。对纳入的随机对照研究(randomized controlled trial, RCT)使用Jadad评分量表进行质量评价,对纳入的非随机对照试验使用Minors量表进行质量评价。数据提取后使用stata18.0软件进行Meta分析,连续型变量合并的效应量使用标准化均数差(standard mean difference, SMD)及其95%可信区间(credibility interval, CI)表示。计数资料使用率及95%CI表示。结果纳入1篇RCT,1篇回顾性队列研究,8篇自身前后对照试验,共计194例研究对象。Meta分析结果显示:托珠单抗治疗激素抵抗或不耐受的中重度TAO可以显著减低CAS评分［SMD=-4.99, 95%CI(-6.30~-3.67), P<0.05］,减少眼球突出度［SMD:-0.81,95%CI(-1.35,-0.27), P<0.05］,降低TSI/TRAb［SMD=-0.86,95%CI(-1.17~-0.55), P<0.05］,不良反应事件发生率为［Rate:0.35,95%CI(0.20,0.51), P<0.05］,轻中度占大多数,严重不良反应事件发生少见。结论托珠单抗对激素抵抗或不耐受的中重度甲状腺相关性眼病有较好的治疗效果,并且耐受性较好。

Abstract: Objective To investigate the clinical efficacy of tocilizumab(TCZ)in the treatment of moderate-to-severe thyroid-associated ophthalmopathy(TAO)with steroid resistance or intolerance. Methods Relevant clinical studies on tocilizumab for moderate-to-severe TAO with steroid resistance or intolerance were retrieved from the following Chinese and English databases: CNKI, CBM, Wanfang Data, VIP, PubMed, Web of Science, Embase, and Cochrane Library. The retrieval period was from the establishment of each database to April 11, 2024. Evaluation indicators included clinical activity score(CAS), exophthalmos, thyroid-stimulating immunoglobulin(TSI)or thyroid-stimulating hormone receptor antibody(TRAb), and adverse reactions. The quality of included randomized controlled trials(RCTs)was assessed using the Jadad scale, while the quality of non-randomized controlled trials was evaluated with the Minors scale. After data extraction, meta-analysis was performed using Stata 18.0 software. For continuous variables, the combined effect size was expressed as standardized mean difference(SMD)with 95% confidence interval(CI). For count data, the rate with 95%CI was used. Results A total of 1 RCT, 1 retrospective cohort study, and 8 before-after self-controlled trials were included, involving 194 subjects. The meta-analysis results showed that tocilizumab significantly reduced CAS ［SMD=-4.99, 95%CI(-6.30, -3.67), P<0.05］, decreased exophthalmos ［SMD=-0.81, 95%CI(-1.35, -0.27), P<0.05］, and lowered TSI/TRAb ［SMD=-0.86, 95%CI(-1.17, -0.55), P<0.05］. The incidence of adverse reactions was 0.35［95%CI(0.20, 0.51), P<0.05］, with most being mild to moderate and severe adverse reactions being rare. Conclusion Tocilizumab has a good therapeutic effect and favorable tolerance in the treatment of moderate-to-severe TAO with steroid resistance or intolerance.

Key words: Tocilizumab, Thyroid associated ophthalmopathy, Graves Ophthalmopathy, Therapeutic effect, Meta-analysis

中图分类号:

R771.3

雷玉丹,方璐,陈健,彭昌福. 托珠单抗治疗激素抵抗或不耐受的中重度甲状腺相关性眼病临床疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 54-67.

LEI Yudan, FANG Lu, CHEN Jian, PENG Changfu. Meta-analysis of clinical Efficacy of tocilizumab in the treatment of moderate-to-severe thyroid-associated ophthalmopathy with steroid resistance or intolerance[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 54-67.

参考文献 31

[1]	Bahn RS. Current insights into the pathogenesis of Graves'Ophthalmopathy[J]. Horm Metab Res, 2015, 47(10): 773-778. doi: 10.1055/s-0035-1555762
[2]	HUANG Yazhuo, FANG Sijie, ZHANG Shuo, et al. Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development[J]. Taiwan Journal of Ophthalmology. 2020, 10(3):174-180. doi:10.4103/tjo.tjo_18_20
[3]	Hu Y, Chen JH, Lin K, et al. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis[J]. Front Endocrinol(Lausanne), 2023, 14: 1160936. doi: 10.3389/fendo.2023.1160936
[4]	Antonelli A, Fallahi P, Elia G, et al. Graves' disease: Clinical manifestations, immune pathogenesis(cytokines and chemokines)and therapy[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101388. doi: 10.1016/j.beem.2020.101388
[5]	Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy[J]. Exp Eye Res, 2016, 142: 83-91. doi: 10.1016/j.exer.2015.02.007
[6]	Zhang PB, Zhu H. Cytokines in thyroid-associated ophthalmopathy[J]. J Immunol Res, 2022, 2022: 2528046. doi: 10.1155/2022/2528046
[7]	Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy[J]. Thyroid, 2002, 12(3): 193-195. doi: 10.1089/105072502753600124
[8]	Ueland HO, Ueland GÅ, Løvås K, et al. Novel inflammatory biomarkers in thyroid eye disease[J]. Eur J Endocrinol, 2022, 187(2): 293-300. doi: 10.1530/EJE-22-0247
[9]	Hai YP, Saeed MEM, Ponto KA, et al. A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease[J]. Thyroid, 2022, 32(12): 1547-1558. doi: 10.1089/thy.2022.0173
[10]	Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab(actemra)[J]. Hum Vaccin Immunother, 2017, 13(9): 1972-1988. doi: 10.1080/21645515.2017.1316909
[11]	Olivo SA, Macedo LG, Gadotti IC, et al. Scales to assess the quality of randomized controlled trials: a systematic review[J]. Phys Ther, 2008, 88(2): 156-175. doi: 10.2522/ptj.20070147
[12]	Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies(minors): development and validation of a new instrument[J]. ANZ journal of surgery. 2003, 73(9):712-716. doi:10.1046/j.1445-2197.2003.02748.x
[13]	Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant Graves' orbitopathy[J]. Ophthalmic Plast Reconstr Surg, 2014, 30(2): 162-167. doi: 10.1097/IOP.0000000000000037
[14]	Pérez -Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial[J]. Am J Ophthalmol, 2018, 195: 181-190. doi: 10.1016/j.ajo.2018.07.038
[15]	Bennedjaï A, Bouheraoua N, Gatfossé M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves' orbitopathy[J]. Ocul Immunol Inflamm, 2022, 30(2): 500-505. doi: 10.1080/09273948.2020.1808688
[16]	Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 receptor tocilizumab in refractory Graves' orbitopathy: national multicenter observational study of 48 patients[J]. J Clin Med, 2020, 9(9): 2816. doi: 10.3390/jcm9092816
[17]	Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant Graves' orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience[J]. J Clin Med, 2021, 10(4): 706. doi: 10.3390/jcm10040706
[18]	Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab[J]. Clin Endocrinol(Oxf), 2022, 97(3): 363-370. doi: 10.1111/cen.14655
[19]	Smith LD, Moscato EE, Seiff SR. Tocilizumab for the management of thyroid-associated orbitopathy[J]. Ophthalmic Plast Reconstr Surg, 2022, 38(2): 188-192. doi: 10.1097/IOP.0000000000002027
[20]	Dorado Cortez O, Grivet D, Perrillat N, et al. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study[J]. Orbit, 2023, 42(4): 411-417. doi: 10.1080/01676830.2022.2119262
[21]	Pampín-Sánchez R, Martínez-Mugica-Barbosa C, Fonseca-Aizpuru EM, et al. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease[J]. Med Clin(Barc), 2023, 160(3): 113-117. doi: 10.1016/j.medcli.2022.05.007
[22]	Boutzios G, Chatzi S, Goules AV, et al. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study[J]. Front Endocrinol(Lausanne), 2023, 14: 1186105. doi: 10.3389/fendo.2023.1186105
[23]	Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy[J]. Clin Endocrinol(Oxf), 1997, 47(1): 9-14. doi: 10.1046/j.1365-2265.1997.2331047.x
[24]	Sugawa H, Akamizu T, Kosugi S, et al. Presence of heterogeneous thyroid-stimulating antibodies in sera from individual Graves' patients as shown by synthesized thyrotropin receptor peptide application: evidence showing two independent epitopes and a possible recognition of two epitopic regions by one antibody molecule[J]. Eur J Endocrinol, 1995, 133(3): 283-293. doi: 10.1530/eje.0.1330283
[25]	Lantz M, Planck T, Asman P, et al. Increased TRAb and/or low anti-TPO titers at diagnosis of Graves' disease are associated with an increased risk of developing ophthalmopathy after onset[J]. Exp Clin Endocrinol Diabetes, 2014, 122(2): 113-117. doi: 10.1055/s-0033-1363193
[26]	Kotwal A, Stan M. Thyrotropin receptor antibodies-an overview[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(4S Suppl 1): S20-S27. doi: 10.1097/IOP.0000000000001052
[27]	Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update[J]. Autoimmun Rev, 2010, 10(2): 116-122. doi: 10.1016/j.autrev.2010.08.018
[28]	Kahaly GJ. Bioassays for TSH receptor antibodies: quo vadis?[J]. Eur Thyroid J, 2015, 4(1): 3-5. doi: 10.1159/000375445
[29]	Khamisi S, Lundqvist M, Engström BE, et al. Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the management of Graves' orbitopathy[J]. Exp Clin Endocrinol Diabetes, 2023, 131(4): 236-241. doi: 10.1055/a-2021-0596
[30]	Marcocci C, Watt T, Altea MA, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association[J]. Eur J Endocrinol, 2012, 166(2): 247-253. doi: 10.1530/EJE-11-0779
[31]	Macacu A, Autier P, Boniol M, et al. Active and passive smoking and risk of breast cancer: a meta-analysis[J]. Breast Cancer Res Treat, 2015, 154(2): 213-224. doi: 10.1007/s10549-015-3628-4

相关文章 15

[1]	朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[2]	许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[3]	孙春晓,王文晴,岳田,刘济生. 高低累积顺铂剂量同步放化疗治疗鼻咽癌的疗效分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 31-41.
[4]	郑泽皓,魏佳俐,刘嘉涛,周玉麒,孙文婷,李雨轩,白鹏. 特定部位针刺法治疗突发性聋的疗效及安全性评价:一项系统综述和网状Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 114-127.
[5]	米雪芹,李松哲,邓英杰,李圣洋,肖丁齐,樊磊. 质子泵抑制剂与胃黏膜保护剂治疗咽喉反流性疾病临床疗效及安全性对比的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 136-142.
[6]	王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.
[7]	李飏,刘鸫,曹文捷. 红光治疗对近视儿童等效球镜度、眼轴长度及脉络膜厚度影响的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 74-81.
[8]	张真,杨卓莹,周佳妮,张大为,陈仁杰. 环索奈德鼻喷剂治疗季节性过敏性鼻炎疗效与安全的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 13-20.
[9]	毕晓云,马本绪,王心茹,李旭豪,杨继国. 穴位贴敷治疗小儿过敏性鼻炎随机对照试验的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 75-85.
[10]	李泽鹏,李文建,孙志佳. 中成药治疗急性咽炎数据挖掘及网状Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 111-118.
[11]	翟睿,李园,于敬龙,陈溪,郑酉友,刘兆兰,王俊宏. 揿针治疗变应性鼻炎临床疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 35-45.
[12]	张西,邓启成,张震,程瑶,王靖淞,赵锐,刘海. 营养支持对喉癌术后咽瘘影响的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 51-59.
[13]	林曼青,周敏,陈腾宇,李丹,方彩珊,王睿智,朱锦祥,阮岩,徐慧贤,王培源. 中药鼻腔冲洗治疗慢性鼻窦炎术后有效性和安全性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 209-225.
[14]	姜雪莲, 张静月, 卫旭东. 基于Meta分析桥接网络药理学的鼻渊通窍颗粒治疗慢性鼻窦炎的疗效评价及潜在机制研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 226-236.
[15]	黄开月,李雪情,韩国鑫,张勤修. 基于“肺脾”理论指导穴位埋线治疗变应性鼻炎的Meta分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 266-274.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed